Biogen Announces $2 Billion Manufacturing Investment in North Carolina’s Research Triangle Park in Conjunction with its 30th Anniversary
Biogen (NASDAQ:BIIB) has announced a $2 billion investment to expand its manufacturing capabilities in North Carolina's Research Triangle Park (RTP). This significant investment builds upon the company's 30-year manufacturing presence in the region, where it has already invested approximately $10 billion to date.
The expansion will focus on enhancing antisense oligonucleotide capabilities, establishing multi-platform fill finish capabilities, and modernizing manufacturing through advanced automation and AI. As North Carolina's largest biotechnology employer, Biogen currently employs over 1,500 manufacturing and technical staff plus 400 skilled contractors across its Wake County and Durham County campuses.
Biogen (NASDAQ:BIIB) ha annunciato un investimento di 2 miliardi di dollari per ampliare le sue capacità produttive nel Research Triangle Park (RTP) della Carolina del Nord. Questo importante investimento si basa sulla presenza produttiva trentennale dell'azienda nella regione, dove ha già investito circa 10 miliardi di dollari fino ad oggi.
L'espansione sarà focalizzata sul potenziamento delle capacità per oligonucleotidi antisenso, sull'istituzione di capacità multi-piattaforma di riempimento e finitura, e sulla modernizzazione della produzione attraverso automazione avanzata e intelligenza artificiale. Essendo il più grande datore di lavoro biotecnologico della Carolina del Nord, Biogen impiega attualmente oltre 1.500 addetti alla produzione e tecnici più 400 appaltatori qualificati nei suoi campus di Wake County e Durham County.
Biogen (NASDAQ:BIIB) ha anunciado una inversión de 2 mil millones de dólares para expandir sus capacidades de fabricación en el Research Triangle Park (RTP) de Carolina del Norte. Esta inversión significativa se basa en la presencia manufacturera de 30 años de la compañía en la región, donde ya ha invertido aproximadamente 10 mil millones de dólares hasta la fecha.
La expansión se centrará en mejorar las capacidades de oligonucleótidos antisentido, establecer capacidades de llenado y acabado multiplataforma, y modernizar la fabricación mediante automatización avanzada e inteligencia artificial. Como el mayor empleador biotecnológico de Carolina del Norte, Biogen actualmente emplea a más de 1,500 empleados de manufactura y técnicos además de 400 contratistas especializados en sus campus de los condados de Wake y Durham.
Biogen (NASDAQ:BIIB)은 노스캐롤라이나 주 리서치 트라이앵글 파크(RTP)에서 제조 역량을 확장하기 위해 20억 달러 투자를 발표했습니다. 이 중요한 투자는 회사가 이 지역에서 30년간 제조 사업을 운영해온 기반 위에 이루어졌으며, 현재까지 약 100억 달러를 투자했습니다.
이번 확장은 안티센스 올리고뉴클레오타이드 역량 강화, 다중 플랫폼 충전 및 마감 능력 구축, 첨단 자동화 및 인공지능을 통한 제조 현대화에 중점을 둘 예정입니다. 노스캐롤라이나에서 가장 큰 생명공학 고용주인 Biogen은 현재 웨이크 카운티와 더럼 카운티 캠퍼스에서 1,500명 이상의 제조 및 기술 직원과 400명의 숙련 계약자를 고용하고 있습니다.
Biogen (NASDAQ:BIIB) a annoncé un investissement de 2 milliards de dollars pour étendre ses capacités de production dans le Research Triangle Park (RTP) en Caroline du Nord. Cet investissement majeur s'appuie sur la présence manufacturière de 30 ans de l'entreprise dans la région, où elle a déjà investi environ 10 milliards de dollars à ce jour.
L'expansion portera sur le renforcement des capacités en oligonucléotides antisens, la mise en place de capacités multi-plateformes de remplissage et de finition, ainsi que la modernisation de la production grâce à l'automatisation avancée et à l'intelligence artificielle. En tant que plus grand employeur en biotechnologie de Caroline du Nord, Biogen emploie actuellement plus de 1 500 employés de production et techniques ainsi que 400 sous-traitants qualifiés sur ses campus des comtés de Wake et Durham.
Biogen (NASDAQ:BIIB) hat eine Investition von 2 Milliarden US-Dollar angekündigt, um seine Produktionskapazitäten im Research Triangle Park (RTP) in North Carolina auszubauen. Diese bedeutende Investition baut auf der 30-jährigen Produktionspräsenz des Unternehmens in der Region auf, in die bereits etwa 10 Milliarden US-Dollar investiert wurden.
Die Erweiterung konzentriert sich auf die Verbesserung der Fähigkeiten im Bereich Antisense-Oligonukleotide, den Aufbau von Multi-Plattform-Abfüll- und Endbearbeitungskapazitäten sowie die Modernisierung der Produktion durch fortschrittliche Automatisierung und KI. Als größter Biotechnologie-Arbeitgeber in North Carolina beschäftigt Biogen derzeit über 1.500 Produktions- und Technikspezialisten sowie 400 qualifizierte Auftragnehmer an seinen Standorten in Wake County und Durham County.
- New $2 billion investment in manufacturing expansion
- Company is the largest biotechnology employer in North Carolina with over 1,500 employees
- Over 90% of Biogen's commercial medicines have U.S.-based manufacturing
- Investment supports advancement of late-stage clinical pipeline
- Implementation of advanced automation and AI in manufacturing processes
- Significant capital expenditure requirement of $2 billion
- Extended timeline for implementation and return on investment
- Investment builds on Biogen’s 30-year history of manufacturing in the region, with approximately
$10 billion invested to date
CAMBRIDGE, Mass., July 21, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) – today announced it intends to invest an additional
In the next few years, Biogen plans to continue investing in multiple modalities and factories across the company’s two campuses in RTP. These investments will include further expansion of the antisense oligonucleotide (ASO) capabilities and infrastructure, establishing clinical and commercial multi-platform fill finish capabilities, and continuing to modernize manufacturing technologies and controls through further advanced automation and artificial intelligence.
“We are proud of our longstanding commitment to manufacturing innovation, investment, and collaboration with the Research Triangle Park community,” said Nicole Murphy, Head of Pharmaceutical Operations and Technology at Biogen. “Our manufacturing footprint in the United States has played a critical role in Biogen’s history and success, and in advancing the treatments that are making an impact for patients, families, and communities here in the U.S. and around the world. With this investment, we will modernize and expand our manufacturing capability to enable our pipeline and provide resilient patient supply, while continuing to support the skilled and dedicated community of life sciences talent in North Carolina.”
North Carolina’s RTP is home to Biogen's largest manufacturing footprint. As the state's largest biotechnology employer and one of the top five biopharmaceutical employers, Biogen employs over 1,500 manufacturing and technical employees and more than 400 skilled contractors across its Wake County and Durham County campuses. More than
About Biogen’s global manufacturing footprint
Biogen’s overall global manufacturing supply chain strategy aims at ensuring resilient and high-quality patient supply through robust risk management including geographical risk diversification and dual sourcing. In the United States, the Research Triangle Park (RTP) area in North Carolina is the home for Biogen’s largest manufacturing facilities. Our manufacturing operations in North Carolina include seven manufacturing factories across multiple modalities. An eighth state-of-the-art factory is currently under construction and will be operational in the second half of 2025. In addition to state-of-the-art manufacturing, our North Carolina campuses include sophisticated quality control laboratories to ensure the safety, efficacy, and purity of the medicines we produce. More than
About Biogen
Founded in 1978, Biogen is a leading biotechnology company that pioneers innovative science to deliver new medicines to transform patients’ lives and to create value for shareholders and our communities. We apply deep understanding of human biology and leverage different modalities to advance first-in-class treatments or therapies that deliver superior outcomes. Our approach is to take bold risks, balanced with return on investment to deliver long-term growth.
We routinely post information that may be important to investors on our website at www.biogen.com. Follow us on social media - Facebook, LinkedIn, X, YouTube.
Biogen Safe Harbor
This news release contains forward-looking statements, including about the anticipated benefits of new investments in Biogen’s global manufacturing footprint; the potential of Biogen's commercial business and pipeline programs; and risks and uncertainties associated with drug development and commercialization. These forward-looking statements may be accompanied by such words as “aim,” “anticipate,” “assume,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “forecast,” “goal,” “guidance,” “hope,” “intend,” “may,” “objective,” “plan,” “possible,” “potential,” “predict,” “project,” “prospect,” “should,” “target,” “will,” “would,” and other words and terms of similar meaning. Drug development and commercialization involve a high degree of risk, and only a small number of research and development programs result in commercialization of a product. Results in early-stage clinical trials may not be indicative of full results or results from later stage or larger scale clinical trials and do not ensure regulatory approval. You should not place undue reliance on these statements. Given their forward-looking nature, these statements involve substantial risks and uncertainties that may be based on inaccurate assumptions and could cause actual results to differ materially from those reflected in such statements. These forward-looking statements are based on management's current beliefs and assumptions and on information currently available to management. Given their nature, we cannot assure that any outcome expressed in these forward-looking statements will be realized in whole or in part. We caution that these statements are subject to risks and uncertainties, many of which are outside of our control and could cause future events or results to be materially different from those stated or implied in this document, including, among others, uncertainty of long-term success in developing, licensing, or acquiring other product candidates or additional indications for existing products; expectations, plans and prospects relating to product approvals, approvals of additional indications for our existing products, sales, pricing, growth, reimbursement and launch of our marketed and pipeline products; our ability to effectively implement our corporate strategy; the successful execution of our strategic and growth initiatives, including acquisitions; the risk that positive results in a clinical trial may not be replicated in subsequent or confirmatory trials or success in early stage clinical trials may not be predictive of results in later stage or large scale clinical trials or trials in other potential indications; risks associated with clinical trials, including our ability to adequately manage clinical activities, unexpected concerns that may arise from additional data or analysis obtained during clinical trials, regulatory authorities may require additional information or further studies, or may fail to approve or may delay approval of our drug candidates; the occurrence of adverse safety events, restrictions on use with our products, or product liability claims; and any other risks and uncertainties that are described in other reports we have filed with the U.S. Securities and Exchange Commission.
These statements speak only as of the date of this press release and are based on information and estimates available to us at this time. Should known or unknown risks or uncertainties materialize or should underlying assumptions prove inaccurate, actual results could vary materially from past results and those anticipated, estimated or projected. Investors are cautioned not to put undue reliance on forward-looking statements. A further list and description of risks, uncertainties and other matters can be found in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024 and in our subsequent reports on Form 10-Q and Form 10-K, in each case including in the sections thereof captioned “Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” and in our subsequent reports on Form 8-K. Except as required by law, we do not undertake any obligation to publicly update any forward-looking statements whether as a result of any new information, future events, changed circumstances or otherwise.
| MEDIA CONTACT: Biogen Allison Murphy + 1 781 464 3260 public.affairs@biogen.com | INVESTOR CONTACT: Biogen Tim Power +1 781 464 2442 IR@biogen.com |
FAQ
How much is Biogen investing in its North Carolina manufacturing facility in 2025?
How many employees does Biogen have in North Carolina's Research Triangle Park?
What will Biogen's new $2 billion investment be used for?
How much has Biogen invested in North Carolina manufacturing to date?
What percentage of Biogen's commercial medicines are manufactured in the US?
